Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cel-Sci Corp (AMEX:CVM) (was HIV) -- Ignore unavailable to you. Want to Upgrade?

To: Toni Wheeler who wrote (2743)	11/19/1999 12:19:00 PM
From: Toni Wheeler	Read Replies (1) \| Respond to of 2836

It appears that Geert IS NOT sitting on his hands... CEL-SCI Starts Cancer Collaboration in Germany <<<VIENNA, Va., Nov. 19 /PRNewswire/ -- CEL-SCI CORPORATION (Amex: HIV; Berlin Stock Exchange:LSR) announces that it has entered a research collaboration with Drs. Iduna Fichtner and Gabriele Pecher at the Max-Delbruck Center for Molecular Medicine in Berlin, Germany. This agreement marks the 7th collaboration with a major research group by CEL-SCI for its new technology L.E.A.P.S.(TM). The goal of the collaboration with Drs. Fichtner and Pecher is to develop a therapeutic vaccine for breast and/or colon cancer. The collaboration will make use of CEL-SCI's L.E.A.P.S. technology, which directs the immune response by design, in combination with the specialized cancer antigen and animal testing model knowledge of the team in Berlin. The work is being conducted under the umbrella of the Biological Therapeutic Development Group (BTDG) of the European Office for Research and Treatment of Cancer (EORTC). Geert Kersten, Chief Executive Officer of CEL-SCI Corporation, says, "We are pleased by the interest of our collaborators to work with us. It confirms that the L.E.A.P.S. technology is exciting and promising. Our objective is to find the best research teams for certain diseases and to collaborate with them. The ultimate goal is to quickly and cost-effectively advance new therapeutic vaccine candidates into human studies. We are currently talking to a number of other potential European collaborators." The L.E.A.P.S. technology is also the subject of ongoing collaborations at the U.S. Naval Medical Research Center (malaria), National Cancer Institute (cancer), University of Maryland (tuberculosis), the University of Nebraska Medical Center (HIV) and the Northeastern Ohio Universities College of Medicine (herpes simplex). Most recently CEL-SCI announced that it had entered a research collaboration with Noel Rose, M.D., Ph.D., Professor of Pathology and Medicine, at the Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, for the treatment, and possible prevention, of autoimmune myocarditis, a disease affecting the heart muscle. CEL-SCI Corporation is a biopharmaceutical company whose mission is to mobilize the immune system to combat disease. When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinic results demonstrated in preclinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 1998. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. ------------------------------------------------------------------------ SOURCE: ÿCEL-SCI Corporation CONTACT: ÿGeert Kersten Chief Executive Officer of CEL-SCI, 703-506-9460; or Investors, Daryll Strahl for CEL-SCI, 970-377-2216>>>